Pure Global

A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) - Trial NCT05766501

Access comprehensive clinical trial information for NCT05766501 through Pure Global AI's free database. This Phase 3 trial is sponsored by Merck Sharp & Dohme LLC and is currently Recruiting. The study focuses on HIV Infection. Target enrollment is 1300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05766501
Phase 3
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05766501
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
A Phase 3 Open-label Clinical Study of Doravirine/Islatravir (DOR/ISL [100 mg/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL (100 mg/0.75 mg) QD in a Phase 3 Clinical Study

Study Focus

HIV Infection

DOR/ISL

Interventional

drug

Sponsor & Location

Merck Sharp & Dohme LLC

Phoenix,Beverly Hills,Los Angeles,Los Angeles,Los Angeles,Sacramento,Washington,Fort Lauderdale,Fort Pierce,Miami Lakes,Miami,Orlando,Orlando,West Palm Beach,Decatur,Macon,Savannah,Kansas City,Hillsbo, Australia,Canada,Israel,Japan,Puerto Rico,Russian Federation,Taiwan,United States of America

Timeline & Enrollment

Phase 3

Mar 17, 2023

Jan 14, 2026

1300 participants

Primary Outcome

Percentage of Participants with One or More Adverse Event (AE),Percentage of participants who Discontinue Study Intervention Due to an AE

Summary

The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult
 participants with HIV-1 who had been previously treated with DOR/ISL in earlier clinical
 studies. There are no formal hypotheses to be tested in this study.

ICD-10 Classifications

HIV disease resulting in other viral infections
Human immunodeficiency virus [HIV] disease
HIV disease resulting in other bacterial infections
Acute HIV infection syndrome
Unspecified human immunodeficiency virus [HIV] disease

Data Source

ClinicalTrials.gov

NCT05766501

Non-Device Trial